Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Paxil CR Ad Medicalizes "Ordinary" Anxiety, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

TV ads "broaden" use of the antidepressant beyond social anxiety disorder and into attributes that "do not generally require psychopharmacological treatment," FDA ad division letter says. Risk information is minimized by distractions and failure to note contraindications, FDA says.

You may also be interested in...



GSK Handling Of Paxil Data On Pediatric Use Is Subject Of N.Y. Lawsuit

The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.

Wyeth Effexor Promotions Cited For Superiority Claims In FDA Letter

The ad division letter follows an Office of Personnel Management Inspector General investigation into Wyeth's Effexor marketing practices. FDA asserts that Wyeth's claims of superiority to SSRIs are unsubstantiated.

“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says

Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.

Topics

UsernamePublicRestriction

Register

PS059657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel